BioCentury
ARTICLE | Finance

Imperial's diagnostic push

Why Imperial plans to boost diagnostic, medtech investing

February 15, 2016 8:00 AM UTC

Imperial Innovations Group plc (LSE:IVO) is looking to put a fresh £100 million to work to follow its existing portfolio companies and create newcos, with an increasing emphasis on diagnostics and medtech.

The firm has already started ramping up, with its largest-ever diagnostics investment, in Inivata Ltd. Inivata is developing TAm-Seq circulating tumor DNA (ctDNA) analysis technology as a non-invasive blood test with an initial focus on solid tumor diagnostics...